Ashwani Mehta, MD
Interventional Cardiology · Kansas City, KSNPI 1871695858
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in KS, where the typical reported total is $8,846.
Across 210 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$752
- Amgen$476
- AstraZeneca$474
- Sanofi-aventis U.S. LLC$364
- Boston Scientific$308
- Merck$271
- plus $1K from 17 others
Across 18 payments — averaging $1840.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$33K
What the payments were for
- Food & beverage$3,740100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 40 | $752 |
| Amgen | 28 | $476 |
| AstraZeneca | 31 | $474 |
| Sanofi-aventis U.S. LLC | 24 | $364 |
| Boston Scientific | 11 | $308 |
| Merck | 16 | $271 |
| Pfizer | 10 | $163 |
| Novartis | 10 | $153 |
| Shockwave Medical, Inc | 1 | $142 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $138 |
| Amarin Pharma, Inc. | 6 | $99 |
| Boehringer Ingelheim | 6 | $84 |
| Irhythm Technologies, Inc. | 3 | $58 |
| Alnylam Pharmaceuticals Inc. | 3 | $49 |
| Impulse Dynamics (USA) Inc. | 2 | $44 |
| Medtronic | 2 | $37 |
| Scpharmaceuticals Inc. | 2 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,740 in reported general payments places this provider in the 25th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $223,365 |
| EntrestoSacubitril/Valsartan | 102 | $129,160 |
| JardianceEmpagliflozin | 76 | $89,562 |
| Repatha SureclickEvolocumab | 86 | $71,583 |
| XareltoRivaroxaban | 18 | $30,118 |
| FarxigaDapagliflozin Propanediol | 29 | $19,848 |
| Praluent PenAlirocumab | 14 | $9,900 |
| Ezetimibe | 474 | $8,359 |
| Atorvastatin Calcium | 735 | $6,772 |
| Torsemide | 292 | $5,017 |
| Metoprolol Succinate | 460 | $4,661 |
| Rosuvastatin Calcium | 372 | $4,371 |
| Carvedilol | 423 | $3,424 |
| Losartan Potassium | 322 | $2,913 |
| Spironolactone | 328 | $2,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $223,365196 claims |
| NovartisEntresto | $153 | $129,160102 claims |
| Boehringer IngelheimJardiance | $84 | $89,56276 claims |
| Johnson & JohnsonXarelto | $13 | $30,11818 claims |
| AstraZenecaFarxiga | $474 | $19,84829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Kansas City
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- John SerfasKansas City$31K
- Venkat PasnooriKansas City$21K
- Peter TadrosKansas City$20K
- Eric HockstadKansas City$15K
- Georges HajjKansas City$5K
- Maheedhar GedelaWichita$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.